bempegaldesleukin (NKTR-214)

News alerts, weekly reports and conference planners

Company:

BMS, Nektar Therap, Ono Pharma

Drug class:

IL-2 stimulant, CD122 agonist

Related drugs:

›

PD-1 expression	Sarcoma	PD-1 expression	Sarcoma	nivolumab + NKTR-214 Sensitive: C3 – Early Trials nivolumab + NKTR-214 Sensitive : C3	nivolumab + NKTR-214 Sensitive: C3 – Early Trials nivolumab + NKTR-214 Sensitive : C3
CD8 positive	Fibrosarcoma	CD8 positive	Fibrosarcoma	NKTR-214 Sensitive: D – Preclinical NKTR-214 Sensitive : D	NKTR-214 Sensitive: D – Preclinical NKTR-214 Sensitive : D
CD8 positive	Colorectal Cancer	CD8 positive	Colorectal Cancer	NKTR-214 Sensitive: D – Preclinical NKTR-214 Sensitive : D	NKTR-214 Sensitive: D – Preclinical NKTR-214 Sensitive : D

Associations
(3)